Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent |
Multiple Sclerosis | United States | NCT04933552 | |
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN |
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis | Phase3 | Argentina Brazil China France Germany Greece Israel Italy Japan Netherlands Spain Switzerland Turkey (Türkiye) United Kingdom United States View all |
NCT03955445 |
Regulatory Post-Marketing Surveillance Study for Brolucizumab |
Neovascular Age-related Macular Degeneration | South Korea | NCT04985487 | |
A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea |
Graft-versus-Host Disease | South Korea | NCT05621733 | |
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function |
Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase2 | France Germany Italy Spain United States View all |
NCT06004661 |
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria |
Uncomplicated Plasmodium Falciparum Malaria | Phase2 | Burkina Faso Côte d’Ivoire Gabon Ghana Kenya Uganda View all |
NCT05750628 |
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) |
Lupus Erythematosus, Systemic, Lupus Nephritis | Phase2 | Australia Austria Brazil Czechia Denmark France Germany Hungary Israel Italy Japan Netherlands Norway Romania Saudi Arabia Singapore South Korea Spain Sweden Switzerland Taiwan United Kingdom United States View all |
NCT06581198 |
Secukinumab Open Label Roll-over Extension Protocol |
Autoimmunity, Inflammation | Phase4 | Czechia Poland Russia Spain United States View all |
NCT04638647 |
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis |
Multiple Sclerosis | Phase4 | Taiwan | NCT04480853 |
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
Chronic Spontaneous Urticaria | Phase3 | Argentina Canada China Germany Hong Kong Italy Japan Malaysia Netherlands Poland Singapore South Africa Spain Thailand Turkey (Türkiye) United Kingdom United States View all |
NCT05677451 |